MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

6.830 +0.390 (+6.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TransCode Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
Via Investor Brand Network
News headline image
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances RNA Cancer Therapy as 15 Patients Dosed in Phase 1a Trial
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Sets 1-for-28 Reverse Stock Split Effective May 15
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138
Via Investor Brand Network
News headline image
Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
Via AB Newswire
Topics Intellectual Property
InvestorNewsBreaks – TransCode Therapeutics Inc. (NASDAQ: RNAZ) Secures $10M in Registered Direct Offering
Via Investor Brand Network
News headline image
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split
Split designed to achieve compliance with Nasdaq minimum bid price requirements 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
Study demonstrates that TransCode’s lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewal 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics, Inc. Announces Closing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics, Inc. Announces Pricing of Public Offering
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
TransCode shares to remain listed on Nasdaq 
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
From TransCode Therapeutics, Inc.
Via GlobeNewswire
News headline image
TransCode Therapeutics Open Letter to Shareholders
From TransCode Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story